[ad_1]
Posted on Facebook, the LSE professor of health policy, Elijah Mosialos, refers to the efficacy of the AstraZeneca, Novavax and Johnson & Johnson vaccines.
“After the impressive efficacy of mRNA vaccines, many are concerned about other vaccines,” said Mosialos, who cited the data.
«The 3 vaccines from AstraZeneca and Johnson & Johnson (as well as Sputnik-V) are similar in development technology and are viral vectors, while those from Novavax are protein-type. However, the results of the clinical studies refer to different analysis periods after vaccination, so we cannot compare, one by one, neither these 4 vaccines with each other, nor with the initial 2.“Writes the teacher
«If the vaccine simply smoothed out infections, there would be no reduction in the overall positivity of the PCR tests (but rather a ‘quantitative’ difference in the result of the PCR test), as the authors claim.“He points out, among other things.
«It is important that 4 companies (Pfizer, Moderna, Novavax and AZ) modify vaccines to better protect us from the serious symptoms that variant (re) infections can cause. Scientists and companies are analyzing the new data and modifying the vaccines, respectively. But it is important that governments and citizens respond with vigilance“He also states.
